Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 6Gynecologic 5Plasma cell 1Lymphoid 1Breast 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × TER 286 × Gynecologic × Clear all
NCT00022347 2013-06-26

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00102973 2012-05-31

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 3 Completed
244 enrolled
Gynecologic

Ovarian Neoplasms

NCT00038428 2011-07-25

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Telik

Phase 2 Completed
40 enrolled
Gynecologic

Ovarian Neoplasms

NCT00051948 2011-07-25

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

NCT00052065 2011-07-25

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Telik

Phase 1/2 Completed
28 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡